Evidence map›Paper›PMID 40970869›Full record

ArticleImmunotherapy2025

Durable response to an anti-CD25 antibody-drug conjugate and anti-PD-1 antibody in ovarian carcinoma: a case report.

Faraah Bekheet, Melanie Ashland, Rochelle Reyes, Oliver Dorigo, Amer Karam, Christopher T Chen

Abstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in Immunotherapy, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Faraah BekheetDivision of Oncology, Department of Medicine, Stanford University School of Medicine, Stanford, CA, USA.
Melanie AshlandDivision of Oncology, Department of Medicine, Stanford University School of Medicine, Stanford, CA, USA.
Rochelle ReyesDivision of Oncology, Department of Medicine, Stanford University School of Medicine, Stanford, CA, USA.
Oliver DorigoDivision of Gynecologic Oncology, Stanford University School of Medicine, Stanford, CA, USA.
Amer KaramDivision of Gynecologic Oncology, Stanford University School of Medicine, Stanford, CA, USA.
Christopher T ChenDivision of Oncology, Department of Medicine, Stanford University School of Medicine, Stanford, CA, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Although PD-1 checkpoint inhibition has improved outcomes for some cancer types, a substantial proportion of solid tumors still do not respond, in part due to inadequate cytotoxic CD8+ T-cell infiltration and survival within the tumor microenvironment (TME). CD25+ regulatory T-cells (Tregs) are a subset of T-cells that play a key role in suppressing CD8+ T-cell activity. Depletion of Tregs in the TME could thus enhance anti-cancer immune responses. Here, we present the experience of a patient with platinum-resistant ovarian carcinoma who achieved a durable partial response on a phase 1 clinical trial of an anti-CD25 antibody-drug conjugate combined with pembrolizumab. Notably, her tumor response correlated with a reduction in CD25+ Tregs on paired tumor biopsies and further deepened after treatment discontinuation. This case provides early proof-of-concept that Treg depletion combined with PD-1/PD-L1 inhibitors can lead to anti-cancer efficacy in refractory diseases and offers key lessons to guide future development of anti-Treg therapeutics.

Indexed as

Antibodies, Monoclonal, HumanizedImmune Checkpoint InhibitorsImmunoconjugatesInterleukin-2 Receptor alpha SubunitOvarian NeoplasmsProgrammed Cell Death 1 ReceptorT-Lymphocytes, RegulatoryAgedFemaleHumansTreatment OutcomeTumor MicroenvironmentAntibodies, Monoclonal, HumanizedImmune Checkpoint InhibitorsImmunoconjugatesInterleukin-2 Receptor alpha SubunitPDCD1 protein, humanpembrolizumabProgrammed Cell Death 1 Receptorcancer immunologycase reportcheckpoint inhibitorsclinical immunologyImmunotherapyovarian cancer

Identifiers

PMID40970869
PMCPMC12582050

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.